Anthony O Caggiano
Works at
Chief medical officer
Sources: reporter.nih.gov
Grants and prizes
R01, Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 Months, R01AG065248, 2020–2027, 25 Aug 2026
R01, A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Dementia with Lewy Bodies, R01AG071643, 2021–2025, 25 Aug 2023
Sources: reporter.nih.gov